Maridebart cafraglutide is a novel peptide-antibody conjugate that serves as a GLP-1 receptor agonist and GIP receptor antagonist. This compound exhibits potent agonistic activity against GLP-1 receptors across species, with EC50 values of 24.4 pM for human, 5.7 pM for cynomolgus monkey, 2.4 pM for rat, and 123 pM for mouse. Additionally, it shows antagonistic effects on GIP receptors with IC50 values of 46.4 nM in human, 26.5 nM in cynomolgus monkey, and 822.3 nM in rat models. Maridebart cafraglutide is primarily used for investigating mechanisms of obesity and type 2 diabetes.
Maridebart cafraglutide is a novel peptide-antibody conjugate that serves as a GLP-1 receptor agonist and GIP receptor antagonist. This compound exhibits potent agonistic activity against GLP-1 receptors across species, with EC50 values of 24.4 pM for human, 5.7 pM for cynomolgus monkey, 2.4 pM for rat, and 123 pM for mouse. Additionally, it shows antagonistic effects on GIP receptors with IC50 values of 46.4 nM in human, 26.5 nM in cynomolgus monkey, and 822.3 nM in rat models. Maridebart cafraglutide is primarily used for investigating mechanisms of obesity and type 2 diabetes.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
